Novartis Aktie
Kursziele der Novartis-Aktie in CHF
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| JP Morgan Chase & Co. | 135,00 CHF | +7,26% | 10.08.2026 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 120,00 CHF | -4,66% | 27.07.2026 | |
| Jefferies & Company Inc. | 110,00 CHF | -12,60% | 23.07.2026 | |
| DZ BANK | - | - | 22.07.2026 | |
| Bernstein Research | 132,84 CHF | +5,55% | 22.07.2026 | |
| Deutsche Bank AG | 140,00 CHF | +11,23% | 22.07.2026 | |
| UBS AG | 116,00 CHF | -7,83% | 22.07.2026 | |
| Goldman Sachs Group Inc. | 111,00 CHF | -11,81% | 30.06.2026 | |
| Barclays Capital | 120,00 CHF | -4,66% | 29.04.2026 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 8 | 0 | 1 | 164,21 GBP | - |
| Bayer | 7 | 2 | 0 | 55,31 EUR | +12,60% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 1 | 2 | 0 | 5,70 EUR | +53,39% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 5 | 2 | 21,17 GBP | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 4 | 4 | 0 | 141,00 EUR | 0,00% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 2 | 6 | 1 | 123,10 CHF | -2,19% |
| Pfizer Inc. | 2 | 5 | 1 | 27,14 USD | +1,95% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Roche Holding AG Inhaber-Partizipationsschein | 3 | 4 | 1 | - | - |
| Sanofi S.A. | 5 | 4 | 0 | 93,53 EUR | +23,73% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |




